These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36740128)

  • 1. Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M
    Khan AM; Atia-Tul-Wahab ; Farooq S; Ullah A; Choudhary MI
    Int J Biol Macromol; 2023 Apr; 234():123540. PubMed ID: 36740128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an
    Ambrosio FA; Costa G; Romeo I; Esposito F; Alkhatib M; Salpini R; Svicher V; Corona A; Malune P; Tramontano E; Ceccherini-Silberstein F; Alcaro S; Artese A
    J Chem Inf Model; 2023 Jun; 63(11):3601-3613. PubMed ID: 37227780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of SARS-CoV-2 main protease inhibitors from FDA-approved drugs by artificial intelligence-supported activity prediction system.
    Komatsu H; Tanaka T; Ye Z; Ikeda K; Matsuzaki T; Yasugi M; Hosoda M
    J Biomol Struct Dyn; 2023 Mar; 41(5):1767-1775. PubMed ID: 34984963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
    Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
    J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.
    Ahmed MZ; Zia Q; Haque A; Alqahtani AS; Almarfadi OM; Banawas S; Alqahtani MS; Ameta KL; Haque S
    J Infect Public Health; 2021 May; 14(5):611-619. PubMed ID: 33866129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
    Verma AK; Aggarwal R
    Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M
    Sultan A; Ali R; Ishrat R; Ali S
    J Biomol Struct Dyn; 2022; 40(23):12848-12862. PubMed ID: 34569411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
    Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
    J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing.
    Prakash A; Borkotoky S; Dubey VK
    J Biomol Struct Dyn; 2023 Apr; 41(7):3014-3024. PubMed ID: 35266856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
    Martorana A; Gentile C; Lauria A
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential SARS-CoV-2 protease M
    Kouznetsova VL; Huang DZ; Tsigelny IF
    Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-silico drug repurposing for targeting SARS-CoV-2 main protease (M
    Sharma S; Deep S
    J Biomol Struct Dyn; 2022 Apr; 40(7):3003-3010. PubMed ID: 33179568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
    Chakraborti S; Bheemireddy S; Srinivasan N
    Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.